CAREDX, INC. (CDNA) FY2026 YTD Q2 Statement of Cash Flows

Statement of Cash Flows

2026-01-01 to 2026-06-30

Swipe to see the full flow
CAREDX, INC. cash flow reconciliation, Jan 1, 2026 through Jun 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Orange marks positive customer-advance and deferred-revenue changes that add to operating cash in the reconciliation. These are net changes, not gross customer receipts. Negative changes are neutral reconciliation adjustments; they do not by themselves identify cash payments. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Net income (loss) → Net cash from operating activities: $34,937,000.00Net income (loss) → Operating adjustments reconciliation: $78,508,000.00Stock-based compensation → Operating adjustments reconciliation: $20,457,000.00Accrued and other liabilities → Operating adjustments reconciliation: $11,218,000.00Depreciation and amortization → Operating adjustments reconciliation: $6,710,000.00Amortization of right-of-use assets → Operating adjustments reconciliation: $2,656,000.00Inventory → Operating adjustments reconciliation: $1,926,000.00Amortization of premium and accretion of discount on marketable securities, net → Operating adjustments reconciliation: $1,414,000.00Deferred revenue → Operating adjustments reconciliation: $943,000.00Accounts payable → Operating adjustments reconciliation: $859,000.00Loss on disposal of asset → Operating adjustments reconciliation: $210,000.00Other → Operating adjustments reconciliation: $66,000.00Operating adjustments reconciliation → Gain on sale of lab products business: $112,966,000.00Operating adjustments reconciliation → Prepaid and other assets: $8,379,000.00Operating adjustments reconciliation → Operating leases liabilities, net: $2,963,000.00Operating adjustments reconciliation → Accrued compensation: $621,000.00Operating adjustments reconciliation → Accounts receivable: $38,000.00Proceeds from sale of lab products business, net → investing reconciliation: $164,792,000.00Sales of marketable securities → investing reconciliation: $114,636,000.00Maturities of marketable securities → investing reconciliation: $59,744,000.00investing reconciliation → Net cash from investing activities: $291,645,000.00investing reconciliation → Purchases of marketable securities: $39,850,000.00investing reconciliation → Additions of property and equipment: $5,677,000.00investing reconciliation → Purchase of long term investment: $2,000,000.00Net cash used in financing activities → financing reconciliation: $18,409,000.00Proceeds from issuance of common stock under employee stock purchase plan → financing reconciliation: $2,497,000.00Proceeds from exercise of stock options → financing reconciliation: $1,354,000.00financing reconciliation → Repurchase and retirement of common stock: $12,232,000.00financing reconciliation → Taxes paid related to net share settlement of restricted stock units: $8,528,000.00financing reconciliation → Payment of contingent consideration: $1,500,000.00Exchange-rate effect → Cash sources and uses: $4,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $65,980,000.00Net cash from operating activities → Cash sources and uses: $34,937,000.00Net cash from investing activities → Cash sources and uses: $291,645,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $374,157,000.00Cash sources and uses → Net cash used in financing activities: $18,409,000.00Net income (loss): $113,445,000.00Net income (loss)+$113.45 MStock-based compensation: $20,457,000.00Stock-based compensation+$20.46 MDepreciation and amortization: $6,710,000.00Depreciation & amortization+$6.71 MAmortization of right-of-use assets: $2,656,000.00Operating lease amortization+$2.66 MLoss on disposal of asset: $210,000.00Other asset gain & loss+$210.00 KGain on sale of lab products business: -$112,966,000.00Business sale gain & loss−$112.97 MRevaluation of contingent consideration to estimated fair value: $0.00Amortization of premium and accretion of discount on marketable securities, net: $1,414,000.00Investment discount & premium+$1.41 MOther: $66,000.00Other non-cash items+$66.00 KAccounts receivable: -$38,000.00Accounts receivable−$38.00 KInventory: $1,926,000.00Inventories+$1.93 MPrepaid and other assets: -$8,379,000.00Prepaid & other current, net−$8.38 MOperating leases liabilities, net: -$2,963,000.00Operating lease liabilities, net−$2.96 MAccounts payable: $859,000.00Trade payables+$859.00 KAccrued compensation: -$621,000.00Accrued salaries & wages−$621.00 KAccrued and other liabilities: $11,218,000.00Other accrued liabilities+$11.22 MDeferred revenue: $943,000.00Deferred revenue+$943.00 KNet cash from operating activities: $34,937,000.00Operating cash+$34.94 MOperating adjustments reconciliation: $124,967,000.00Proceeds from issuance of common stock under employee stock purchase plan: $2,497,000.00Stock plan proceeds+$2.50 MTaxes paid related to net share settlement of restricted stock units: -$8,528,000.00Stock-award tax withholding−$8.53 MProceeds from exercise of stock options: $1,354,000.00Stock option exercises+$1.35 MPayment of contingent consideration: -$1,500,000.00Contingent consideration paid−$1.50 MRepurchase and retirement of common stock: -$12,232,000.00Common stock repurchases−$12.23 MNet cash used in financing activities: -$18,409,000.00. Cash required to fund net payments.Financing cash−$18.41 Mfinancing reconciliation: $22,260,000.00Purchases of marketable securities: -$39,850,000.00Marketable securities purchases−$39.85 MMaturities of marketable securities: $59,744,000.00Marketable securities maturities+$59.74 MSales of marketable securities: $114,636,000.00Sales of marketable securities+$114.64 MPurchase of long term investment: -$2,000,000.00Long-term investment purchases−$2.00 MProceeds from sale of lab products business, net: $164,792,000.00Business sales, net of cash+$164.79 MAdditions of property and equipment: -$5,677,000.00PP&E purchases−$5.68 MNet cash from investing activities: $291,645,000.00Investing cash+$291.65 Minvesting reconciliation: $339,172,000.00Cash sources and uses: $392,566,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $65,980,000.00Beginning cash$65.98 MEnding cash: Cash, cash equivalents, and restricted cash: $374,157,000.00Ending cash$374.16 MExchange-rate effect: $4,000.00FX effect+$4.00 KCASH RECONCILIATIONOperatingflowsInvestingflowsFinancingflowsFree cash flow$29.26 MOperating cash − cash spent on PP&ECash flow / Net income0.31×Operating cash flow ÷ net incomeNet cash change+$308.18 MEnding cash − beginning cash
Chart details

CAREDX, INC. cash flow reconciliation, Jan 1, 2026 through Jun 30, 2026

Cash flows for Jan 1, 2026 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Dec 31, 2025. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Dec 31, 2025
65,980,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
34,937,000 US dollars. Net cash provided.
Net income (loss)
113,445,000 US dollars
Stock-based compensation
20,457,000 US dollars
Depreciation and amortization
6,710,000 US dollars
Amortization of right-of-use assets
2,656,000 US dollars
Loss on disposal of asset
210,000 US dollars
Gain on sale of lab products business
negative 112,966,000 US dollars
Revaluation of contingent consideration to estimated fair value
0 US dollars
Amortization of premium and accretion of discount on marketable securities, net
1,414,000 US dollars
Other
66,000 US dollars
Accounts receivable
negative 38,000 US dollars
Inventory
1,926,000 US dollars
Prepaid and other assets
negative 8,379,000 US dollars
Operating leases liabilities, net
negative 2,963,000 US dollars
Accounts payable
859,000 US dollars
Accrued compensation
negative 621,000 US dollars
Accrued and other liabilities
11,218,000 US dollars
Deferred revenue
943,000 US dollars
Investing activities
291,645,000 US dollars. Net cash provided.
Purchases of marketable securities
negative 39,850,000 US dollars
Maturities of marketable securities
59,744,000 US dollars
Sales of marketable securities
114,636,000 US dollars
Purchase of long term investment
negative 2,000,000 US dollars
Proceeds from sale of lab products business, net
164,792,000 US dollars
Additions of property and equipment
negative 5,677,000 US dollars
Financing activities
negative 18,409,000 US dollars. Net cash used.
Proceeds from issuance of common stock under employee stock purchase plan
2,497,000 US dollars
Taxes paid related to net share settlement of restricted stock units
negative 8,528,000 US dollars
Proceeds from exercise of stock options
1,354,000 US dollars
Payment of contingent consideration
negative 1,500,000 US dollars
Repurchase and retirement of common stock
negative 12,232,000 US dollars
Operating adjustment reconciliation
124,967,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
22,260,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
339,172,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
4,000 US dollars
Ending cash on Jun 30, 2026
374,157,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
392,566,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
308,177,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
0.31×. Operating cash flow divided by reconciliation net income for the same period. Black from 0.90× through 1.10×; green above 1.10×; red below 0.90×. Color uses the unrounded ratio.
Operating cash flow
34,937,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
5,677,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
29,260,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net income exceeds operating cash. The diagram allocates $34.94M of net income directly to operating cash and $78.51M to the adjustment junction, where it combines with other additions to reconcile deductions. This is an accounting presentation, not a tracing of cash receipts.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: 34,937,000 US dollars minus 5,677,000 US dollars equals 29,260,000 US dollars.
CAREDX, INC. (CDNA) FY2026 YTD Q2 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!